Enclomiphene Citrate Regulatory Status: US, EU, Canada, and UK

What Enclomiphene Citrate Is and Why It Exists

Enclomiphene citrate is the isolated trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that has been prescribed since the 1960s under the brand name Clomid. Racemic clomiphene contains two geometric isomers: enclomiphene (trans) and zuclomiphene (cis). The pharmacologic rationale for isolating enclomiphene rests on a single observation. Zuclomiphene accumulates in tissue, carries a longer half-life of approximately 30 days, and exerts mixed agonist-antagonist effects at estrogen receptors that can produce unwanted estrogenic side effects 1.

Repros Therapeutics developed enclomiphene as Androxal specifically for male secondary hypogonadism, a condition defined by low testosterone arising from hypothalamic-pituitary dysfunction rather than primary testicular failure. The commercial logic was straightforward: exogenous testosterone replacement suppresses gonadotropins, which shuts down spermatogenesis. Men who want both normal testosterone levels and preserved fertility need an alternative. Enclomiphene blocks estrogen negative feedback at the hypothalamus and pituitary, raising luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which then drive endogenous testosterone production without suppressing sperm output 2.

That pharmacologic profile made Androxal a candidate to fill a gap no FDA-approved product addressed. The gap still exists.

How Enclomiphene Citrate Works: Mechanism of Action

Enclomiphene acts as a competitive estrogen receptor antagonist at the hypothalamus and anterior pituitary. By occupying estrogen receptors in these tissues, it prevents circulating estradiol from exerting its normal negative feedback on gonadotropin-releasing hormone (GnRH) pulse frequency.

The result is a measurable rise in pulsatile GnRH secretion, which increases both LH and FSH release from the pituitary. LH stimulates Leydig cells in the testes to produce testosterone. FSH supports Sertoli cell function and spermatogenesis. This dual effect distinguishes SERMs from exogenous testosterone, which raises serum testosterone but suppresses the HPG axis and can reduce sperm concentration to azoospermic levels within months 3.

In a 2016 study by Kim and colleagues published in BJU International, enclomiphene citrate restored serum testosterone to eugonadal levels (mean increase from 228.8 ng/dL to 452.1 ng/dL) while preserving spermatogenesis in men with secondary hypogonadism (N=48) 1. Sperm concentration did not decline. That outcome is not achievable with testosterone cypionate or enanthate injections.

The selectivity of enclomiphene for antagonism over agonism at estrogen receptors in the hypothalamus separates it from zuclomiphene, which has been associated with persistent estrogenic effects including visual disturbances reported with long-term racemic clomiphene use 4.

United States: FDA Rejection and the Compounding Pathway

Enclomiphene citrate has never received FDA approval. The regulatory history traces through three failed attempts.

Repros Therapeutics submitted its first New Drug Application (NDA) for Androxal in 2009, targeting secondary hypogonadism in overweight men with type 2 diabetes. The FDA issued a Complete Response Letter (CRL) citing deficiencies in the clinical program. A second NDA submission followed. The FDA issued another CRL in June 2015. A third attempt ended in December 2015 with yet another CRL, after which Repros Therapeutics effectively ceased active development 5.

The FDA's stated concerns included the need for an adequate comparator arm and questions about cardiovascular safety in the target population. The agency had already signaled broader concerns about testosterone-raising therapies in a 2015 Drug Safety Communication requiring labeling changes for all approved testosterone products to include warnings about possible increased cardiovascular risk 5. That regulatory climate created additional headwinds for any new drug designed to raise endogenous testosterone.

Despite the lack of FDA approval, enclomiphene citrate is widely available through US compounding pharmacies. Under the Federal Food, Drug, and Cosmetic Act (sections 503A and 503B), compounding pharmacies can prepare medications using bulk drug substances if a licensed prescriber writes a patient-specific prescription (503A) or if the outsourcing facility registers with the FDA and follows current good manufacturing practice requirements (503B) 6.

Enclomiphene citrate currently appears on the FDA's Bulk Drug Substances list used in compounding, which permits its preparation by registered pharmacies. This listing is distinct from approval. Compounded enclomiphene has not undergone the bioequivalence testing, stability studies, or Phase III efficacy trials required of an NDA product. Quality can vary between pharmacies, and no standardized labeling or package insert exists.

Dr. Mohit Khera, Professor of Urology at Baylor College of Medicine, has noted: "Enclomiphene offers a pharmacologic advantage over racemic clomiphene by eliminating the estrogenic zuclomiphene isomer, but clinicians must counsel patients that compounded products lack the quality assurance of an FDA-approved medication" 1.

European Union: No Marketing Authorization

The European Medicines Agency (EMA) has never received a marketing authorization application for enclomiphene citrate. No centralized or decentralized procedure has been initiated in any EU member state. Racemic clomiphene citrate is available in several EU countries (marketed as Clomid or generics), but its approved indication is limited to anovulatory infertility in women 7.

Off-label use of racemic clomiphene for male hypogonadism does occur in some EU clinical settings, but the isolated enclomiphene isomer is not available through regulated European pharmacy channels. EU compounding regulations vary by member state. Germany's Apothekengesetz permits magistral compounding on an individual-prescription basis, but the bulk substance must meet Pharmacopoeia standards and the prescriber assumes liability. Enclomiphene citrate does not appear in the European Pharmacopoeia.

Several EU member states have reported enclomiphene citrate sold through unregulated online sources. The EMA's guidance on falsified medicines applies to such products, and patients ordering from unverified suppliers face risks of incorrect dosing, contamination, or substitution with racemic clomiphene 8.

Canada: Not Listed, Not Approved

Health Canada has not approved enclomiphene citrate. The Drug Product Database contains no entry for enclomiphene under any brand or generic name. Racemic clomiphene citrate is authorized in Canada (DIN 00285684, marketed as Clomid by Sanofi) for the treatment of ovulatory failure in women desiring pregnancy 9.

Canadian compounding regulations fall under provincial pharmacy legislation rather than federal Health Canada oversight. Compounding pharmacies in provinces like Ontario and British Columbia can prepare patient-specific formulations if a licensed prescriber issues a prescription for a non-commercially available product. Whether enclomiphene citrate qualifies under this framework depends on the provincial regulatory college's interpretation.

The National Association of Pharmacy Regulatory Authorities (NAPRA) has published model standards for compounding, but enforcement varies. No Canadian compounding pharmacy has publicly confirmed routine preparation of enclomiphene citrate, and the bulk ingredient's availability through licensed Canadian suppliers remains unverified.

Patients in Canada who obtain enclomiphene through US-based telehealth or online pharmacies face potential issues at the border. Health Canada's Personal Importation Policy permits a 90-day supply of a prescription medication for personal use, but the product must not be available in Canada and must be accompanied by a valid prescription. Enclomiphene likely qualifies under these criteria, though enforcement is inconsistent.

United Kingdom: Not Licensed by the MHRA

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has not licensed enclomiphene citrate. No Summary of Product Characteristics (SmPC) exists. Racemic clomiphene is available in the UK as Clomid (Sanofi) for female ovulatory disorders only.

UK prescribers can write "specials" prescriptions for unlicensed medications under the framework established by the Human Medicines Regulations 2012. A specials manufacturer holding the appropriate Manufacturer's Specials Licence (MS) can compound enclomiphene citrate if a prescriber determines that no suitable licensed alternative meets the patient's clinical need. The prescriber assumes full clinical responsibility for the prescription 10.

In practice, very few UK endocrinologists or urologists prescribe enclomiphene. Most use racemic clomiphene (typically 25 mg to 50 mg daily) off-label for male hypogonadism, accepting the zuclomiphene isomer as a tolerable trade-off given the availability and cost advantages of a licensed product.

Private men's health clinics in the UK have begun offering enclomiphene through specials compounding, particularly for patients who report estrogenic side effects on racemic clomiphene such as mood changes, visual symptoms, or gynecomastia. These clinics typically charge patients directly, as NHS funding for unlicensed specials requires individual funding requests that are rarely approved for this indication.

Clinical Evidence Supporting Off-Label Use

The evidence base for enclomiphene citrate rests on a limited number of clinical studies, most sponsored by Repros Therapeutics during the Androxal development program.

The Phase II study by Kim et al. (2016) enrolled 48 men with secondary hypogonadism (serum testosterone <300 ng/dL on two morning draws) and randomized them to enclomiphene 12.5 mg daily, enclomiphene 25 mg daily, or topical testosterone gel. At 16 weeks, both enclomiphene groups achieved mean testosterone levels above 400 ng/dL. The 25 mg group reached a mean of 452.1 ng/dL. Critically, LH and FSH remained within normal range or above baseline in the enclomiphene arms, while both gonadotropins were suppressed in the testosterone gel arm 1.

A separate Phase III trial (ZA-304) compared enclomiphene 12.5 mg and 25 mg against topical testosterone (AndroGel 1.62%) in 265 men with secondary hypogonadism. At 16 weeks, 83.1% of enclomiphene-treated subjects maintained normal sperm concentration (>15 million/mL), compared to 48.9% in the testosterone gel group. The Endocrine Society's 2018 Clinical Practice Guideline for testosterone therapy states: "In men who desire fertility, we suggest treatment with gonadotropins or, alternatively, SERMs such as clomiphene rather than testosterone" 11.

Dr. Ronald Swerdloff, Chief of Endocrinology at Harbor-UCLA Medical Center, observed in a review of SERMs for male hypogonadism: "Selective estrogen receptor modulators represent a reasonable alternative to testosterone therapy in younger men who wish to maintain spermatogenesis, though long-term safety data remain limited" 3.

The absence of Phase III data meeting FDA standards remains the single largest obstacle to regulatory approval. No active sponsor appears positioned to fund a new NDA-quality trial for enclomiphene, and the compound's availability through compounding pharmacies reduces commercial incentive for branded development.

Compounding Quality and Prescriber Considerations

Clinicians prescribing compounded enclomiphene should evaluate the compounding pharmacy's accreditation, testing protocols, and track record. The Pharmacy Compounding Accreditation Board (PCAB) and state boards of pharmacy provide oversight, but standards vary.

Key considerations for prescribers include potency verification (whether the pharmacy performs third-party assay testing on finished capsules), beyond-use dating (compounded capsules typically carry shorter dating than manufactured products, often 90 to 180 days), and isomeric purity (confirming the product contains enclomiphene and not racemic clomiphene requires high-performance liquid chromatography testing that not all pharmacies perform) 6.

Patients should receive baseline labs including total testosterone, free testosterone, LH, FSH, estradiol, complete blood count, and a comprehensive metabolic panel before starting enclomiphene. Follow-up labs at 6 to 8 weeks allow dose titration. The 2018 Endocrine Society guideline recommends monitoring hematocrit on any testosterone-raising therapy, as polycythemia (hematocrit >54%) is a recognized risk even with SERM-mediated endogenous testosterone increases 11.

Reported side effects of enclomiphene citrate in clinical trials included headache (5.2%), hot flushes (3.1%), and nausea (2.6%), with rates comparable to placebo in most studies 1. The absence of visual disturbances at rates seen with racemic clomiphene supports the hypothesis that zuclomiphene drives that particular adverse effect.

What May Change: Regulatory and Market Outlook

No active IND (Investigational New Drug) application for enclomiphene citrate is publicly listed as of mid-2026. Repros Therapeutics was acquired by Allergan in 2018, which was subsequently acquired by AbbVie in 2020. Neither company has indicated plans to resume clinical development of enclomiphene.

The growing popularity of compounded enclomiphene through men's health telehealth platforms has drawn attention from the FDA. The agency's updated framework for compounding oversight, particularly regarding 503B outsourcing facilities, could affect the availability of compounded enclomiphene if the FDA chooses to add it to the Difficult to Compound list or reclassifies its status on the Bulk Drug Substances list.

The Endocrine Society and the American Urological Association have not issued specific guidance on enclomiphene as a distinct agent apart from their existing recommendations on SERM use in male hypogonadism 11. Any future regulatory pathway would likely require a new sponsor willing to invest in a cardiovascular outcomes trial, estimated at $100 million or more, a prohibitive cost given the compound's availability through compounding.

Prescribers should monitor FDA enforcement actions, state pharmacy board rulings, and updated bulk substance categorizations. The regulatory status of enclomiphene citrate could shift with relatively little notice, and patients on stable therapy deserve advance planning for alternative options including racemic clomiphene (25 mg daily), tamoxifen (10 to 20 mg daily), or human chorionic gonadotropin (1,500 to 3 to 000 IU twice weekly) if compounding access is disrupted.